Influenza vaccination in asthmatic children: Effects on quality of life and symptoms

Dept of General Practice, room Ff305, Erasmus MC - University Medical Center Rotterdam, PO Box, 1738, The Netherlands.
European Respiratory Journal (Impact Factor: 7.64). 01/2005; 24(6):925-31. DOI: 10.1183/09031936.04.00060504
Source: PubMed


This study aimed to detect the effect of influenza vaccination on quality of life, symptomatology and spirometry in asthmatic children. A randomised double-blind placebo-controlled trial in 696 (296 in 1999-2000 and 400 in 2000-2001) asthmatic children aged 6-18 yrs, which were vaccinated with either vaccine or placebo, was performed. Children participated for only one influenza season. They recorded symptoms in a diary and reported when symptom scores reached a predefined severity level. If this occurred research nurses visited them twice, first to take a pharyngeal swab and spirometry, and a week later to assess quality of life over the past illness week. Compared with placebo, vaccination improved health-related quality of life in the weeks of illness related to influenza-positive swabs. However, no effect was found for respiratory symptoms recorded in the diaries during those weeks. Similarly, no differences were found for quality of life in all weeks of illness or for respiratory symptoms throughout the seasons. Influenza vaccination was found to have a moderately beneficial effect on quality of life in influenza-positive weeks of illness in children with asthma.

Download full-text


Available from: Johannes C Van der Wouden,
  • Source
    • "That study (a prospective, randomised, double-blind, placebo-controlled trial) compared trivalent-inactivated vaccine with no vaccine. It assessed HRQoL in children with asthma through the Paediatric Asthma Quality of Life Questionnaire (range of possible scores: 1-7, with 7 indicating the highest HRQoL) [49]. Both the vaccinated and the placebo groups experienced worsening of asthma-related HRQoL. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Influenza illness in children causes significant clinical and economic burden. Although some European countries have adopted influenza immunisation policies for healthy children, the debate about paediatric influenza vaccination in most countries of the European Union is ongoing. Our aim was to summarise influenza burden (in terms of health outcomes and economic burden) in children in Western Europe via a systematic literature review. Methods We conducted a systematic literature search of PubMed, EMBASE, and the Cochrane Library (1970-April 2011) and extracted data on influenza burden in children (defined as aged ≤ 18 years) from 50 publications (13 reporting laboratory-confirmed influenza; 37 reporting influenza-like illness). Results Children with laboratory-confirmed influenza experienced hospitalisations (0.3%-20%), medical visits (1.7-2.8 visits per case), antibiotic prescriptions (7%-55%), and antipyretic or other medications for symptomatic relief (76%-99%); young children and those with severe illness had the highest rates of health care use. Influenza in children also led to absenteeism from day care, school, or work for the children, their siblings, and their parents. Average (mean or median) length of absence from school or day care associated with confirmed influenza ranged from 2.8 to 12.0 days for the children, from 1.3 to 6.0 days for their siblings, and from 1.3 to 6.3 days for their parents. Influenza negatively affected health-related quality of life in children with asthma, including symptoms and activities; this negative effect was smaller in vaccinated children than in non-vaccinated children. Conclusions Influenza burden in children is substantial and has a significant direct impact on the ill children and an indirect impact on their siblings and parents. The identified evidence regarding the burden of influenza may help inform both influenza antiviral use in children and paediatric immunisation policies in European countries.
    BMC Public Health 11/2012; 12(1):968. DOI:10.1186/1471-2458-12-968 · 2.26 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: 1. Systematische reviews betwijfelen de klinische effectiviteit van influenzavaccinatie. 2. Influenzavaccinatie zorgt niet voor minder astma-exacerbaties bij kinderen. 3. Influenzavaccinatie veroorzaakt geen astma-exacerbaties. 4. Voor het beoordelen van de (kosten)effectiviteit van routinematige vaccinatie is de gemiddelde klinische incidentie van influenza de enige juiste maat. astma-beschouwing-groepspraktijk-influenza-kinderen-vaccinatie
    Huisarts en wetenschap 12/2005; 48(13):36-40. DOI:10.1007/BF03084115
  • [Show abstract] [Hide abstract]
    ABSTRACT: Looijmans-van den Akker I, Opstelten W, Hak E, Groeneveld K, Knottnerus JA. Griepvaccinatie: herziening van de indicatiestelling een advies van de Gezondheidsraad. Huisarts Wet 2008;51(4): In maart 2007 bracht de Gezondheidsraad een advies uit over de herziening van de indicatiestelling voor griepvaccinatie. De raad pleit voor een uitbreiding van de indicatiestelling naar alle personen van 60 tot 65 jaar, gezondheidszorgpersoneel en gezinsleden van mensen met een zeer hoog risico op ernstige ziekte en sterfte in geval van griep. De Gezondheidsraad adviseert ook om kinderen met astma tegen griep te blijven vaccineren, maar ziet onvoldoende wetenschappelijke onderbouwing om de indicatie voor patiënten met furunculose en hun gezinsleden te handhaven. In dit artikel bespreken we hoe de doelgroepen met een indicatie voor griepvaccinatie geselecteerd zijn. We gaan ook in op de reactie van de minister van Volksgezondheid, Welzijn en Sport (VWS) op het advies. Looijmans-van den Akker I, Opstelten W, Groeneveld K, Knottnerus JA. Influenza vaccination: revision of the indication; recommendations by the Health Council. Huisarts Wet 2008;51(4):… In March 2007 the Health Council of the Netherlands issued recommendations to the Minister of Health, Welfare and Sport regarding the revision of the indication for influenza vaccination. Core points of the recommendations are the extension of the indication to all persons of 60 to 65 years of age, healthcare personnel and family members of individuals who are at particularly high risk of major illness and mortality should they become infected with influenza. It is also recommended to continue offering influenza vaccination to children with asthma. The Health Council did however find insufficient scientific grounds to maintain the indication for patients with furunculosis and their family members. This article details the arguments used in the selection of groups indicated for influenza vaccination as well as the Minister’s response to the recommendations. beschouwing-gezondheidsraad-influenza-vaccinatie
    Huisarts en wetenschap 04/2008; 51(4):169-173. DOI:10.1007/BF03086719
Show more